<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00928330</url>
  </required_header>
  <id_info>
    <org_study_id>GDC4627g</org_study_id>
    <secondary_id>GO01302</secondary_id>
    <nct_id>NCT00928330</nct_id>
  </id_info>
  <brief_title>Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy</brief_title>
  <official_title>A Phase Ib, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Activity of Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This multicenter, Phase Ib study is an open label, dose escalation, three-arm study
      evaluating the safety, tolerability, pharmacokinetics, and activity of oral (PO) GDC 0941
      administered in combination with either intravenous (IV) infusion of T-DM1 or IV infusion of
      trastuzumab.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in cardiac function</measure>
    <time_frame>Through study completion or early study discontinuation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in vital signs, physical findings, and clinical laboratory results during and following administration of study drugs that result in dose modification, dose delay, or discontinuation of T-DM1 and/or GDC 0941</measure>
    <time_frame>Through study completion or early study discontinuation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence, nature, and severity of adverse events</measure>
    <time_frame>Through study completion or early study discontinuation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters of T-DM1 and GDC-0941 (total exposure, maximum serum concentration, and minimum concentration)</measure>
    <time_frame>Through study completion or early study discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From study treatment initiation to the first occurrence of disease progression or death on study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response based on investigator assessment</measure>
    <time_frame>Confirmed response &gt;/= 4 weeks after initial documentation of response</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Time from initial complete or partial response to the time of disease progression or death on study</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0941</intervention_name>
    <description>Oral repeating dose</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Intravenous repeating dose</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trastuzumab-MCC-DM1</intervention_name>
    <description>Intravenous repeating dose</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically documented locally advanced or metastatic breast cancer that has
             progressed on at least one trastuzumab-based regimen in the metastatic or locally
             advanced setting

          -  HER2-positive disease documented by one of the following results using FDA-approved
             testing methods: FISH-positive, chromogenic in situ hybridization (CISH)-positive, or
             IHC 3 + by local laboratory assessment

          -  Life expectancy &gt;= 90 days

          -  Agreement to use an effective form of contraception for the duration of the study

        Exclusion Criteria:

          -  History of Grade &gt;= 3 hypersensitivity reaction to trastuzumab, or Grade &gt;= 1 with the
             most recent trastuzumab infusion before study entry, or continued requirement for
             prolonged trastuzumab infusions to prevent hypersensitivity reactions

          -  History of intolerance to trastuzumab and/or adverse events related to trastuzumab
             that resulted in trastuzumab being permanently discontinued

          -  Prior anti-cancer therapy (e.g., biologic or other targeted therapy, chemotherapy,
             hormonal therapy) within 2 weeks prior to Day 1

          -  Prior investigational anti-cancer therapy within 4 weeks prior to Day 1

          -  Grade &gt;= 2 peripheral neuropathy

          -  History of Grade &gt;= 3 hyperglycemia (fasting)

          -  History of Type 1 or Type 2 diabetes requiring daily medication

          -  History of clinically significant cardiac or pulmonary dysfunction

          -  History of malabsorption syndrome or other condition that would interfere with enteral
             absorption

          -  Clinically significant history of liver disease, including cirrhosis, current alcohol
             abuse, or current known active infection with HIV, hepatitis B virus, or hepatitis C
             virus

          -  Any condition requiring anticoagulants, such as warfarin, heparin, or thrombolytic
             agents

          -  Any condition requiring &gt; 2 grams of acetaminophen daily

          -  Need for current chronic corticosteroid therapy

          -  Pregnancy, lactation, or breast-feeding

          -  Current severe, uncontrolled systemic disease (e.g., clinically significant
             cardiovascular, pulmonary, or metabolic disease)

          -  Major surgical procedure or significant traumatic injury within 28 days prior to Day
             1, or anticipation of the need for major surgery during the course of study treatment

          -  Symptomatic hypercalcemia requiring continued use of bisphosphonate therapy

          -  Known brain metastases that are untreated, symptomatic, or require therapy to control
             symptoms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2009</study_first_submitted>
  <study_first_submitted_qc>June 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2009</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TDM-1</keyword>
  <keyword>HER2</keyword>
  <keyword>HER2+</keyword>
  <keyword>HER2+ Breast Cancer</keyword>
  <keyword>HER-2</keyword>
  <keyword>MBC</keyword>
  <keyword>Trastuzumab emtansine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ado-trastuzumab emtansine</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Maytansine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

